女性乳腺癌相关性心房颤动的研究现状  

Research Status of Female Breast Cancer-Associated Atrial Fibrillation

作　　者：杨仙 陈芸霖 殷跃辉 易鑫[1] 杨敏 崔犇 YANG Xian;CHEN Yunlin;YIN Yuehui;YI Xin;YANG Min;CUI Ben(Chongqing Medical University Graduate School,Chongqing 400010,China;Department of Cardiology,The Second Affiliated Hospital of Chongqing Medical University,Chongqing 400010,China)

机构地区：[1]重庆医科大学研究生院,重庆400010 [2]重庆医科大学附属第二医院心血管内科,重庆400010

出　　处：《心血管病学进展》2023年第8期676-680,共5页Advances in Cardiovascular Diseases

基　　金：国家自然科学基金(82200365);中国博士后科学基金(2021M700631);重庆博士后研究项目特别资助(2020149)。

摘　　要：心房颤动(AF)和乳腺癌均为临床常见疾病,发病率及患病率均呈上升趋势。研究表明,女性乳腺癌患者比一般人群存在更高的AF风险,但二者之间的机制尚不完全明确。另外,女性是AF患者发生卒中的危险因素之一,乳腺癌的存在会增加缺血风险及出血风险,使抗凝效果难以预测,且目前对于乳腺癌合并AF患者抗凝方案尚无权威指南明确推荐。现就女性乳腺癌相关性AF的流行病学、机制、抗凝治疗等相关研究进行综述。Atrial fibrillation and breast cancer are both common clinical diseases,and their incidence and prevalence are increasing.Studies have shown that women with breast cancer have a higher risk of atrial fibrillation than the general population,but the mechanism is not completely clear.In addition,women are one of the risk factors for stroke in patients with atrial fibrillation,and the presence of breast cancer will increase the risk of ischemia and bleeding,making it difficult to predict the anticoagulant effect.At present,there is no authoritative guideline to recommend anticoagulant regimen for patients with breast cancer and atrial fibrillation.This article reviews the epidemiology,mechanism and anticoagulant therapy of female breast cancer-associated atrial fibrillation.

关 键 词：心房颤动 乳腺癌 机制 抗凝 

分 类 号：R737.9[医药卫生—肿瘤] R541.75[医药卫生—临床医学]